Dominari (NASDAQ:DOMH) Stock Price Up 6.5% – Should You Buy?

Dominari Holdings Inc. (NASDAQ:DOMH)’s stock price rose 6.5% on Monday . The stock traded as high as $6.11 and last traded at $5.88. Approximately 128,153 shares changed hands during trading, a decline of 66% from the average daily volume of 378,101 shares. The stock had previously closed at $5.52.

Analyst Ratings Changes

Several analysts recently commented on DOMH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dominari in a report on Wednesday, October 8th. Wall Street Zen upgraded Dominari from a “sell” rating to a “buy” rating in a report on Saturday, August 16th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Dominari currently has an average rating of “Sell”.

Dominari Trading Up 6.5%

The firm has a market capitalization of $91.40 million, a PE ratio of -2.48 and a beta of 0.75. The business has a 50-day moving average of $6.38 and a 200 day moving average of $5.47.

Dominari (NASDAQ:DOMH) last announced its earnings results on Monday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter. Dominari had a negative net margin of 36.01% and a negative return on equity of 94.32%. The business had revenue of $34.10 million for the quarter.

Dominari Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Friday, September 26th. Investors of record on Wednesday, September 3rd were paid a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, September 3rd.

Institutional Investors Weigh In On Dominari

A number of institutional investors and hedge funds have recently bought and sold shares of DOMH. Connective Capital Management LLC bought a new stake in Dominari in the 2nd quarter worth approximately $1,446,000. PFG Investments LLC bought a new stake in Dominari in the 1st quarter worth approximately $566,000. Jane Street Group LLC bought a new stake in Dominari in the 2nd quarter worth approximately $158,000. Magnus Financial Group LLC bought a new stake in Dominari in the 2nd quarter worth approximately $136,000. Finally, Geode Capital Management LLC lifted its position in Dominari by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock worth $361,000 after buying an additional 1,866 shares during the last quarter. 42.48% of the stock is owned by hedge funds and other institutional investors.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.